Drug Profile
Eflapegrastim - Hanmi Pharmaceutical/Assertio Therapeutics
Alternative Names: Eflafegrastim; eflapegrastim-xnst; HM-10460A; HNK-460; LAPS-GCSF; Long-acting G-CSF analogue; ROLONTIS; ROLVEDON; SPI-2012Latest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Developer Assertio Therapeutics; Hanmi Pharmaceutical
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Immunoglobulin Fc fragments; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 31 Jul 2023 Assertio Holdings closed the proposed acquisition of Spectrum Pharmaceuticals and its eflapegrastim-xnst injection asset
- 01 Feb 2023 The Centers for Medicare and Medicaid Services (CMS) issues a permanent reimbursement J-code for , J1449 for Eflapegrastim , effective April 1, 2023
- 07 Dec 2022 The National Comprehensive Cancer Network® Supportive Care Guidelines (NCCN Guidelines) adds Eflapegrastim-xnst for Neutropenia